AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01048125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiographic evaluation
Description: Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
Study NCT01048125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation
Description: Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
Study NCT03593161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humor therapy
Description: Clown visits
Study NCT03549273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glizigen® + Ocoxin-Viusid®
Description: * Glizigen® spray, topical use, 2 times a day for 6 months with an interruption for 2 months at the end of the third month.~* Ocoxin®-Viusid® 60 ml daily (1 vial every 12 hours) by oral route for 8 months, preferably administered after breakfast and lunch, without interruption.
Study NCT01362400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPI 504 plus Docetaxel
Description: 450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)
Study NCT01362400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Docetaxel
Description: 450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)
Study NCT04536415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir Phosphate 75 mg capsules
Description: Capsules, 75 mg, single, oral dose
Study NCT04536415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamiflu capsules 75 mg
Description: Capsules, 75 mg, single, oral dose
Study NCT03711071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workshop ICE training
Description: The workshop includes training in communication skills in relation to evidence based medicine.
Study NCT00893594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan with naprosyn
Description: Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
Study NCT00893594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
Study NCT03267095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy sessions .
Description: In this intervention songs compose by the therapist will be use for the study. The songs included the target word .The target words will be selecte from functional vocabularies that typically developing 3years old children can use effectively in everyday interactions.The general criteria for vocabulary words included: names of familiar objects and persons, functional action words such as words for social control , and emotional words . Inherent musical structures structures and organized musical patterns in the songs will be provide .The patients will reflect on the music therapy activity as singing the song together.
Study NCT01936649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AdreView (Iobenguane I 123 Injection)
Description: AdreView 10 mCi as a single i.v administration
Study NCT01858584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrotuss
Description: Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~* Infants weighing \<5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~* Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day
Study NCT02963467 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cigarette
Description: smoking 4 conventional cigarettes
Study NCT02963467 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: dummy cigarette
Description: smoking a dummy cigarette
Study NCT02050048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of Lactated Ringer's (LR) Solution
Description: Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~* initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~* LR fluid infusion during the procedure at 5 cc/kg/hr~* Post-procedure bolus of 20 cc/kg over 90 minutes
Study NCT02050048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Lactated Ringer's (LR) Solution
Description: Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~* initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~* LR fluid infusion during the procedure at 5 cc/kg/hr~* Post-procedure bolus of 20 cc/kg over 90 minutes
Study NCT03510143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neoveil (Polyglycolic Acid Mesh)
Description: Apply the Neoveil (Polyglycolic Acid Mesh) in the neck node dissection area in thyroid cancer surgery.
Study NCT01996319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVA149
Description: QVA149 (110/50 µg) once a day via Breezhaler® device
Study NCT01996319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo once a day via Breezhaler® device
Study NCT04367701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hemolysis
Description: Authors measured free plasma hemoglobin concentration in gram
Study NCT02445378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aromatherapy and Essential Oils
Description: Undergo aromatherapy and essential oils
Study NCT02445378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Undergo placebo intervention using rose water
Study NCT02445378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00674908 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Easy Five
Description: Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
Study NCT03756233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.
Study NCT00548431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: Standard dose 25 mg/m\^2/day. Can be increased up to 75 mg/m\^2/day if the myelosuppression is acceptable (ANC>0.5 T-count >50)
Study NCT01858584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: thickened milk
Description: Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
Study NCT01780558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: natural cycles
Description: the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-L-Asparaginase
Description: Given by intravenous (IV) or intramuscular (IM) injection.
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia L-Asparaginase
Description: To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or intravenously (IV).
Study NCT01780558 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: estradiol and progesterone
Description: oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
Study NCT03616080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: soccer play program
Description: once a week for an hour of a soccer program for 8 weeks
Study NCT00117338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
Study NCT00117338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Pbo for a study approximately 120 minutes in duration
Study NCT03312946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modellata
Description: treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
Study NCT02616029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablets administered orally once daily
Study NCT04450355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam 80mg/day
Description: continuous nefopam infusion
Study NCT04450355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: continuous normal saline infusion
Study NCT02021123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin 100mg single dose iv
Description: Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
Study NCT02527876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: High Intensity Interval Training
Study NCT02527876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity
Description: Moderate Intensity Training
Study NCT02527876 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Control
Description: Delayed Control
Study NCT02527876 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: FitBit Flex
Description: Use to measure increase in Physical Activity
Study NCT02527876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit Flex
Description: Use to measure increase in Physical Activity
Study NCT02806778 — intervention group
Intervention type: OTHER
Intervention: BIS Monitor-guided sedation
Description: The patients enrolled in the study will undergo BIS Monitor-guided sedation. Standard BIS Monitor will be used for the procedure to monitor the depth of sedation.
Study NCT02806778 — intervention group
Intervention type: OTHER
Intervention: Jugular bulb catheter
Description: Jugular bulb catheter will be implanted in the patients enrolled in the study.
Study NCT01782599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual nicotine patch and electronic cigarette
Study NCT00003210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given subcutaneously
Study NCT00003210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02711345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: ERK Inhibitor
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given orally (PO).
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given intravenously (IV).
Study NCT02203097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial pressure of CO2 at the end of an exhaled breath
Description: Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
Study NCT02203097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
Study NCT03894904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papaverine
Description: 0.12 mg/mL papaverine administered as soon as the arterial catheter is placed and secured, and 0.12 mg/mL papaverine administered one hour after initial dose
Study NCT03894904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
Study NCT04807660 — intervention group
Intervention type: OTHER
Intervention: middle ear fluid sample
Description: middle ear fluid sample for each enrrolled children
Study NCT02472561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit Physical Activity Monitor
Description: Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.
Study NCT02472561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Glucometer
Description: Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.
Study NCT02472561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Blood Pressure
Description: Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.
Study NCT01091285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Foley Catheter 16-19 H
Study NCT01091285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Balloon Catheter
Description: Double Balloon Catheter for 16-19H
Study NCT00831246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum - Extra Winterfresh
Description: Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
Study NCT00831246 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Post-Op Care
Description: Patients are given standard post-op care with clear liquid diet as tolerated.
Study NCT03894904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: 2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
Study NCT02000258 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Double-bundle ACL reconstruction
Study NCT02000258 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
Study NCT02815774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: all subjects were given SP2086 50mg only one time.
Study NCT00973570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TABADO program
Description: The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
Study NCT03347708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDCT
Description: Discogenic Cells + Sodium Hyaluronate Vehicle
Study NCT03347708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Sodium Chloride Solution
Study NCT03347708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate Vehicle
Study NCT03901898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training, audit, and reminders
Description: Briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter), and re-audit at 6 months.
Study NCT03901898 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention after 6 months (wait list)
Description: After 6 months, practices receive the intervention: briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter).
Study NCT02571036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets
Study NCT02571036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 10 mg and 50 mg formulated tablets
Study NCT02352233 — intervention group
Intervention type: PROCEDURE
Intervention: RETROVIEW colonoscope
Description: withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
Study NCT03766360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Analytical Psychotherapy (FAP)
Description: The intervention itself is based on the procedures of Functional Analytic Psychotherapy, a behavioral intervention focusing on improving social functioning.
Study NCT01625403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBNP
Description: intravenous administration of rhBNP 0.01 µg/kg/min
Study NCT01625403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: standard of care for heart failure
Study NCT01344018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT01344018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Study NCT01344018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT03655860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMEOX
Description: SIMEOX is a device generating a succession of gentle depression at the mouth.
Study NCT02321839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraviteal Ranibizumab 0.5mg
Description: Intraviteal Ranibizumab 0.5mg
Study NCT01622764 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Molecular imaging with 89Zr-RO5323441
Description: Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
Study NCT02581527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)